PMID- 35907033
OWN - NLM
STAT- MEDLINE
DCOM- 20221028
LR  - 20221222
IS  - 1619-7089 (Electronic)
IS  - 1619-7070 (Print)
IS  - 1619-7070 (Linking)
VI  - 49
IP  - 13
DP  - 2022 Nov
TI  - Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance 
      perfusion measurements and [(18)F]FET PET in patients with suspected recurrent 
      anaplastic astrocytoma and glioblastoma.
PG  - 4677-4691
LID - 10.1007/s00259-022-05917-3 [doi]
AB  - PURPOSE: Both amino acid positron emission tomography (PET) and magnetic 
      resonance imaging (MRI) blood volume (BV) measurements are used in suspected 
      recurrent high-grade gliomas. We compared the separate and combined diagnostic 
      yield of simultaneously acquired dynamic contrast-enhanced (DCE) perfusion MRI 
      and O-(2-[(18)F]-fluoroethyl)-L-tyrosine ([(18)F]FET) PET in patients with 
      anaplastic astrocytoma and glioblastoma following standard therapy. METHODS: A 
      total of 76 lesions in 60 hybrid [(18)F]FET PET/MRI scans with DCE MRI from 
      patients with suspected recurrence of anaplastic astrocytoma and glioblastoma 
      were included retrospectively. BV was measured from DCE MRI employing a 
      2-compartment exchange model (2CXM). Diagnostic performances of maximal 
      tumour-to-background [(18)F]FET uptake (TBR(max)), maximal BV (BV(max)) and 
      normalised BV(max) (nBV(max)) were determined by ROC analysis using 6-month 
      histopathological (n = 28) or clinical/radiographical follow-up (n = 48) as 
      reference. Sensitivity and specificity at optimal cut-offs were determined 
      separately for enhancing and non-enhancing lesions. RESULTS: In progressive 
      lesions, all BV and [(18)F]FET metrics were higher than in non-progressive 
      lesions. ROC analyses showed higher overall ROC AUCs for TBR(max) than both 
      BV(max) and nBV(max) in both lesion-wise (all lesions, p = 0.04) and in 
      patient-wise analysis (p < 0.01). Combining TBR(max) with BV metrics did not 
      increase ROC AUC. Lesion-wise positive fraction/sensitivity/specificity at 
      optimal cut-offs were 55%/91%/84% for TBR(max), 45%/77%/84% for BV(max) and 
      59%/84%/72% for nBV(max). Combining TBR(max) and best-performing BV cut-offs 
      yielded lesion-wise sensitivity/specificity of 75/97%. The fraction of 
      progressive lesions was 11% in concordant negative lesions, 33% in lesions only 
      BV positive, 64% in lesions only [(18)F]FET positive and 97% in concordant 
      positive lesions. CONCLUSION: The overall diagnostic accuracy of DCE BV imaging 
      is good, but lower than that of [(18)F]FET PET. Adding DCE BV imaging did not 
      improve the overall diagnostic accuracy of [(18)F]FET PET, but may improve 
      specificity and allow better lesion-wise risk stratification than [(18)F]FET PET 
      alone.
CI  - (c) 2022. The Author(s).
FAU - Henriksen, Otto M
AU  - Henriksen OM
AUID- ORCID: 0000-0002-1011-6934
AD  - Dept. of Clinical Physiology Nuclear Medicine and PET, Copenhagen University 
      Hospital Rigshospitalet, Copenhagen, Denmark. 
      otto.moelby.henriksen.01@regionh.dk.
FAU - Hansen, Adam E
AU  - Hansen AE
AD  - Dept. of Radiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, 
      Denmark.
AD  - Dept. of Clinical Medicine, Faculty of Health and Medical Science, University of 
      Copenhagen, Copenhagen, Denmark.
FAU - Muhic, Aida
AU  - Muhic A
AD  - Dept. of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, 
      Denmark.
FAU - Marner, Lisbeth
AU  - Marner L
AD  - Dept. of Clinical Physiology Nuclear Medicine and PET, Copenhagen University 
      Hospital Rigshospitalet, Copenhagen, Denmark.
AD  - Dept. of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital 
      Bispebjerg, Copenhagen, Denmark.
FAU - Madsen, Karine
AU  - Madsen K
AD  - Dept. of Clinical Physiology Nuclear Medicine and PET, Copenhagen University 
      Hospital Rigshospitalet, Copenhagen, Denmark.
FAU - Moller, Soren
AU  - Moller S
AD  - Dept. of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, 
      Denmark.
FAU - Hasselbalch, Benedikte
AU  - Hasselbalch B
AD  - Dept. of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, 
      Denmark.
FAU - Lundemann, Michael J
AU  - Lundemann MJ
AD  - Dept. of Clinical Physiology Nuclear Medicine and PET, Copenhagen University 
      Hospital Rigshospitalet, Copenhagen, Denmark.
AD  - Dept. of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, 
      Denmark.
FAU - Scheie, David
AU  - Scheie D
AD  - Dept. of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, 
      Denmark.
FAU - Skjoth-Rasmussen, Jane
AU  - Skjoth-Rasmussen J
AD  - Dept. of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, 
      Denmark.
FAU - Poulsen, Hans S
AU  - Poulsen HS
AD  - Dept. of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, 
      Denmark.
FAU - Larsen, Vibeke A
AU  - Larsen VA
AD  - Dept. of Radiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, 
      Denmark.
FAU - Larsson, Henrik B W
AU  - Larsson HBW
AD  - Dept. of Clinical Physiology Nuclear Medicine and PET, Copenhagen University 
      Hospital Rigshospitalet, Copenhagen, Denmark.
AD  - Dept. of Clinical Medicine, Faculty of Health and Medical Science, University of 
      Copenhagen, Copenhagen, Denmark.
FAU - Law, Ian
AU  - Law I
AD  - Dept. of Clinical Physiology Nuclear Medicine and PET, Copenhagen University 
      Hospital Rigshospitalet, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20220730
PL  - Germany
TA  - Eur J Nucl Med Mol Imaging
JT  - European journal of nuclear medicine and molecular imaging
JID - 101140988
RN  - 42HK56048U (Tyrosine)
SB  - IM
MH  - Humans
MH  - *Glioblastoma/diagnostic imaging
MH  - *Brain Neoplasms/pathology
MH  - Retrospective Studies
MH  - Positron-Emission Tomography/methods
MH  - *Astrocytoma/diagnostic imaging
MH  - Tyrosine/metabolism
MH  - Magnetic Resonance Imaging/methods
MH  - Perfusion
MH  - Magnetic Resonance Spectroscopy
PMC - PMC9605929
OTO - NOTNLM
OT  - Amino acid tracers
OT  - Blood volume
OT  - Glioma
OT  - Magnetic resonance imaging
OT  - Perfusion imaging
OT  - Positron emission tomography
COIS- The authors declare no competing interests.
EDAT- 2022/07/31 06:00
MHDA- 2022/10/29 06:00
PMCR- 2022/07/30
CRDT- 2022/07/30 11:14
PHST- 2022/02/10 00:00 [received]
PHST- 2022/07/16 00:00 [accepted]
PHST- 2022/07/31 06:00 [pubmed]
PHST- 2022/10/29 06:00 [medline]
PHST- 2022/07/30 11:14 [entrez]
PHST- 2022/07/30 00:00 [pmc-release]
AID - 10.1007/s00259-022-05917-3 [pii]
AID - 5917 [pii]
AID - 10.1007/s00259-022-05917-3 [doi]
PST - ppublish
SO  - Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4677-4691. doi: 
      10.1007/s00259-022-05917-3. Epub 2022 Jul 30.